Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05502315
Phase: Phase 2
Trial Summary: This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rana McKay, MD
Acronym
: CANOPY

Pin It on Pinterest